薬学臨床系薬理学分野
代替医療薬学・実験治療学研究室

HOKURIKU UNIVERSITY

研究業績（2000年以降）

著書・総説

  1. 光本泰秀，補完代替医療特論ー薬学教育における補完代替医療－，応用細胞補完代替医療学　第2巻（猪岡尚志，光本泰秀監修）太陽書房，2022；pp15-23．
  2. 室山明子．パーキンソン病の進行抑制を目指した神経保護代替医療アプローチ (Review)，YAKUGAKU ZASSHI (日本薬学会), 2013；133, pp849-56.
  3. 光本泰秀．補完代替医療の現状－特に中枢神経疾患に関して－，応用細胞補完代替医療学　第1巻（猪岡尚志，光本泰秀編著）大学教育出版，2012；pp12-8.

学術論文

  1. Kidani S, Ukezono M, Takano Y, Mitsumoto Y. A falling trap test for quantitative evaluation of anxiety in C57BL/6N mice.（submitted）
  2. Mitsumoto Y, Nagai Y, Takata R, Mori A. REM sleep deprivation enhances vulnerability of striatal dopaminergic neurons to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in mice. Psychogeriatrics 2020 Jan;20(1):129-130.
  3. Mitsumoto Y, Takamori S, Kishida K. Psychosocial stress enhances susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in C57BL/6N mice. Biomed Res. 2019 Dec;40(6):251-255.
  4. Mitsumoto Y, Sato R, Tagawa N, Kato I. Rubiscolin-6, a δ-opioid peptide from spinach Rubisco, exerts antidepressant-like effect in restraint-stressed mice. J Nutr Sci Vitaminol. 2019 April;65(2):202-204.
  5. Mitsumoto Y, Mori A. Acute restraint stress augments 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity via increased toxin uptake into the brain in C57BL/6 mice. Neurosci Bull. 2018 Oct;34(5):849-853.
  6. Ohmoto M, Takahashi T, Kubota Y, Kobayashi S, Mitsumoto Y. Genetic influence of dopamine receptor, dopamine transporter, and nicotine metabolism on smoking cessation and nicotine dependence in a Japanese population. BMC Genet. 2014 Dec 20;15(1):151.
  7. Kobayashi S, Yokoyama S, Maruta T, Muroyama A, Yoshikawa H, Mitsumoto Y. Attenuation of nicotine-evoked Ca2+ influx by antibody to the nicotinic acetylcholine receptor α3 subunits in human embryonic kidney cells. Adv Biosci Biotechnol. 2013 Jun;4(6A):9-14.
  8. Kobayashia S, Yokoyama S, Maruta T, Negami M, Muroyama A, Mitsumoto Y, Iwasa K, Yamada M, Yoshikawa H. Autoantibody-induced internalization of nicotinic acetylcholine receptor α3 subunit exogenously expressed in human embryonic kidney cells. J Neuroimmunol. 2013 Apr 15;257(1-2):102-6.
  9. Ohmoto M, Sakaishi K, Hama A, Morita A, Nomura M, Mitsumoto Y. Association Between Dopamine Receptor 2 TaqIA Polymorphisms and Smoking Behavior With an Influence of Ethnicity: A Systematic Review and Meta-Analysis Update. Nicotine Tob Res. 2013 Mar;15(3):633-42.
  10. Ohmoto M, Hirakoshi M, Mitsumoto Y. Effects of Moderating Factors Including Serotonin Transporter Polymorphisms on Smoking Behavior: A Systematic Review and Meta-analysis Update. Nicotine Tob Res. 2013 Feb;15(2):572-82.
  11. Muroyama A, Fujita A, Lv C, Kobayashi S, Fukuyama Y, Mitsumoto Y. Magnolol protects against MPTP/MPP+-induced toxicity via inhibition of oxidative stress in in vivo and in vitro models of Parkinson's disease. Parkinson's Disease 2012 Article ID 985157.
  12. Kobayashi S, Muroyama A, Matsushima H, Yoshimura I, Mitsumoto Y. Oral administration of coenzyme Q10 reduces MPTP-induced loss of dopaminergic nerve terminals in the striatum in mice. Neurol Sci. 2012 Feb;33(1):195-9.
  13. Muroyama A, Kobayashi S, Mitsumoto Y. Loss of striatal dopaminergic terminals during the early stage in response to MPTP injection in C57BL/6 mice. Neurosci Res. 2011 Apr;69(4):352-5.
  14. Takano A, Muroyama A, Mitsumoto Y. Effects of different intensity of forced exercise on MPTP-induced neurotoxicity in C57BL/6 mice. Neurosci Res. 2010; 68, Supplement 1:e430.
  15. Iijima C, Muroyama A, Mitsumoto Y. Changes in emotional behavior induced by water immersion restraint stress in mice. Neurosci Res. 2010; 68, Supplement 1:e428.
  16. Nomura S, Muroyama A, Mitsumoto Y. Early changes in the mitochondrial membrane potential induced by MPP+ in human neuroblastoma SH-SY5Y cells. Neurosci Res. 2010; 68, Supplement 1:e258.
  17. Nagasaka K, Kanai Y, Muroyama A, Mitsumoto Y. Intense exercise-induced depression-like behavior is improved by imipramine in mice. Neurosci Res. 2009; 65, Supplement 1:S255.
  18. Mitsumoto Y, Kobayashi S, Matsushima H, Muroyama A, Yoshimura I. Oral administration of coenzyme Q(10) prevents cytochrome c release from mitochondria induced by 1-methyl-4-phenylpyridinium ion in mouse brain synaptosomes. Neurosci Lett. 2009 Sep 29;463(1):22-5.
  19. Sugino H, Futamura T, Mitsumoto Y, Maeda K, Marunaka Y. Atypical antipsychotics suppress production of proinflammatory cytokines and up-regulate interleukin-10 in lipopolysaccharide-treated mice.Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):303-7.
  20. Muroyama A, Inaka M, Matsushima H, Sugino H, Marunaka Y, Mitsumoto Y. Enhanced susceptibility to MPTP neurotoxicity in magnesium-deficient C57BL/6N mice.Neurosci Res. 2009 Jan;63(1):72-5.
  21. Mitsumoto Y. Mitochondrial nutrition as a strategy for neuroprotection in Parkinson's Disease. Evid Based Complement Alternat Med. 2007 Jun;4(2):263-265.
  22. Ohashi S, Mori A, Kurihara N, Mitsumoto Y, Nakai M. Age-related severity of dopaminergic neurodegeneration to MPTP neurotoxicity causes motor dysfunction in C57BL/6 mice. Neurosci Lett. 2006 Jun 19;401(1-2):183-7.
  23. Koga K, Mori A, Ohashi S, Kurihara N, Kitagawa H, Ishikawa M, Mitsumoto Y, Nakai M. H MRS identifies lactate rise in the striatum of MPTP-treated C57BL/6 mice. Eur. J Neurosci. 2006 Feb; 23(4):1077-81.
  24. Zhai H, Nakade K, Oda M, Mitsumoto Y, Akagi M, Sakurai J, Fukuyama Y. Honokiol-induced neurite outgrowth promotion depends on activation of extracellular signal-regulated kinases (ERK1/2). Eur J Pharmacol. 2005 Jun 1;516(2):112-7.
  25. Mori A, Ohashi S, Nakai M, Moriizumi T, Mitsumoto Y. Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice. Neurosci Res. 2005 Mar;51(3):265-74.
  26. Zhai H, Inoue T, Moriyama M, Esumi T, Mitsumoto Y, Fukuyama Y. Neuroprotective effects of 2,5-diaryl-3,4-dimethyltetrahydrofuran neolignans. Biol Pharm Bull. 2005 Feb;28(2):289-93.
  27. Mitsumoto Y, Mori A, Ohashi S, Nakai M, Moriizumi T. Differential effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the olfactory bulb and the striatum in mice. Neurosci Res. 2005 Jan;51(1):111-5.
  28. Zhai H, Nakatsukasa M, Mitsumoto Y, Fukuyama Y. Neurotrophic effects of talaumidin, a neolignan from Aristolochia arcuata, in primary cultured rat cortical neurons. Planta Med. 2004 Jul;70(7):598-602.
  29. Miwa T, Watanabe A, Mitsumoto Y, Furukawa M, Fukushima N, Moriizumi T. Olfactory impairment and Parkinson's disease-like symptoms observed in the common marmoset following administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Acta Otolaryngol Suppl. 2004 Aug;(553):80-4.
  30. Esumi T, Makado G, Zhai H, Shimizu Y, Mitsumoto Y, Fukuyama Y. Efficient synthesis and structure-activity relationship of honokiol, a neurotrophic biphenyl-type neolignan. Bioorg Med Chem Lett. 2004 May 17;14(10):2621-5.
  31. Zhai H, Nakade K, Mitsumoto Y, Fukuyama Y. Honokiol and magnolol induce Ca2+ mobilization in rat cortical neurons and human neuroblastoma SH-SY5Y cells. Eur J Pharmacol. 2003 Aug 8;474(2-3):199-204.
  32. Nakai M, Mori A, Watanabe A, Mitsumoto Y. 1-methyl-4-phenylpyridinium (MPP+) decreases mitochondrial oxidation-reduction (REDOX) activity and membrane potential (Deltapsi(m)) in rat striatum. Exp Neurol. 2003 Jan;179(1):103-10.
  33. Mori A, Okuyama K, Horie M, Taniguchi Y, Wadatsu T, Nishino N, Shimada Y, Miyazawa N, Takeda S, Niimi M, Kyushiki H, Kondo M, Mitsumoto Y. Alteration of methamphetamine-induced striatal dopamine release in mint-1 knockout mice. Neurosci Res. 2002 Jul;43(3):251-7.
  34. Kitagawa H, Mori A, Shimada J, Mitsumoto Y, Kikuchi T. Intracerebral adenosine infusion improves neurological outcome after transient focal ischemia in rats. Neurol Res. 2002 Apr;24(3):317-23.
  35. Fukuyama Y, Nakade K, Minoshima Y, Yokoyama R, Zhai H, Mitsumoto Y. Neurotrophic activity of honokiol on the cultures of fetal rat cortical neurons. Bioorg Med Chem Lett. 2002 Apr 22;12(8):1163-6.
  36. Mitsumoto Y, Watanabe A, Miyauchi T, Jimma F, Moriizumi T. Stimulation of the regrowth of MPP+-damaged dopaminergic fibers by the treatment of mesencephalic cultures with basigin. J Neural Transm. 2001;108(10):1127-34.
  37. Horie M, Mitsumoto Y, Kyushiki H, Kanemoto N, Watanabe A, Taniguchi Y, Nishino N, Okamoto T, Kondo M, Mori T, Noguchi K, Nakamura Y, Takahashi E, Tanigami A. Identification and characterization of TMEFF2, a novel survival factor for hippocampal and mesencephalic neurons. Genomics. 2000 Jul 15;67(2):146-52.

その他刊行物

  1. 光本泰秀（分担）．第1章 自律神経系に作用する薬，スタンダード薬学シリーズⅡ第6巻　医療薬学Ⅰ．薬の作用と体の変化および薬理・病態・薬物治療（1）(赤池昭紀他編集) 東京化学同人，2015, 10月刊行
  2. 光本泰秀．補完代替医療，ファルマシア (日本薬学会)，2005；41(9)，907．